Treatment of lower respiratory tract infections with ceftriaxone and cefotaxime. A comparative study.

  title={Treatment of lower respiratory tract infections with ceftriaxone and cefotaxime. A comparative study.},
  author={Gabriella Abbate and I. Alagia and Emanuele Giaquinto and V. Leonessa and L Savioli and Paolo Altucci and Mario Caputi and Carmen Guarino and E. Micillo and Emanuele Catena},
  journal={Respiration; international review of thoracic diseases},
  volume={49 3},
The microbiological and clinico-therapeutic efficacy and safety of ceftriaxone were compared with those of cefotaxime in an open randomized trial. Fifty-four adult hospitalized patients (37 males and 17 females) suffering from either acute bronchopneumonia (19) or acute exacerbations of chronic bronchopneumonia (35) have been investigated. Four patients were withdrawn from the trial. Underlying diseases were present in 41 patients. Ceftriaxone was administered at a once-a-day dose of either 1… 
Cefoperazone versus ceftriaxone monotherapy of nosocomial pneumonia.
Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.
Ceftriaxone now has a well-defined place as an appropriate alternative for the parenteral treatment of a variety of infections due to susceptible organisms, as well as for perioperative prophylaxis of surgery, and may offer advantages of greater convenience over other parenTERal antibiotics which are administered more frequently.
Cefotaxime. An update of its pharmacology and therapeutic use.
Cefotaxime represents a valuable 'third generation' cephalosporin of great clinical value in certain infectious conditions, in particular those which are serious and life-threatening and where resistance to therapies is creating a clinical problem.
Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections
  • S. Segev, R. Raz, S. Pitlik
  • Medicine, Biology
    European Journal of Clinical Microbiology and Infectious Diseases
  • 2005
It is indicated that ceftriaxone 1 g/day is as effective as 2 g/ day in the treatment of moderate to severe community-acquired infections and the low-dose form is a more economical means of treating these infections.
Efficacy of Ceftriaxone 1 g daily Versus 2 g daily for The Treatment of Community-Acquired Pneumonia: A Systematic Review with Meta-Analysis
Ceftriaxone dosages of 1 g daily are as safe and effective as other antibiotic regimens for community-acquired pneumonia.
Empiric therapy of severe infections in adults.
  • J. Modai
  • Medicine, Biology
    The American journal of medicine
  • 1990
Drug Utilisation Review (DUR) of the Third Generation Cephalosporins
Six parenteral third generation cephalosporins have been introduced into clinical use in the past 10 years and the 3 most frequently available agents are cefotaxime, ceftriaxone and ceftazidime, characterised by a broad spectrum of activity and increased stability to β-lactamases.
Systemic antibiotic treatment of nosocomial pneumonia
Because further improvement in morbidity and mortality may be limited with antibiotics alone, new emphasis should be placed on prevention of infection and the use of immunotherapy.
Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin.
It was concluded that the in vitro antimicrobial activity of ceftriaxone compared with that of cefotaxime was significantly diminished in the presence of serum albumin.